The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) has agreed the use of romosozumab for treating severe osteoporosis in people after menopause in line with NICE TA791.
Romosozumab will be given a RED traffic light status. Prescribing will be by hospital specialists only using Blueteq forms for initiation.
The romosozumab treatment course is 12 months ONLY.
Patients should be started on anti-resorptive treatment by the specialist team after the romosozumab treatment course is complete.
Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.
